{"id":"calcium-phosphate","rwe":[{"pmid":"41905050","year":"2026","title":"\"Bentogypsum\", a phosphoric acid purification residue: Characterization and implications for environmental and human health risk in Gabes (SE Tunisia).","finding":"","journal":"Journal of hazardous materials","studyType":"Clinical Study"},{"pmid":"41899898","year":"2026","title":"Clinical Evidence on Resorbable Calcium Phosphate Biomaterials for Alveolar Bone Regeneration: A Scoping Review Focusing on Brushite, Monetite, and Tricalcium Phosphates.","finding":"","journal":"Bioengineering (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41898411","year":"2026","title":"Time-Course Evaluation of the In Vivo Resorption Process of Calcium Phosphates/Poly(lactide-co-glycolide) Composites Using Radiological Imaging and Histology.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41897332","year":"2026","title":"Synthetic Modulators of the Vitamin D Receptor: From Structural Innovation to Disease-Specific Applications.","finding":"","journal":"Biomolecules","studyType":"Clinical Study"},{"pmid":"41895242","year":"2026","title":"Longitudinal evaluation of salivary biomarkers and white spot lesion development in patients undergoing fixed orthodontic treatment: A prospective cohort study.","finding":"","journal":"International orthodontics","studyType":"Clinical Study"}],"_fda":{"id":"28fb3178-9aac-406f-a82a-de53d0876f67","set_id":"11cad8ba-6914-420e-bab0-4ca37d33f2e6","openfda":{"unii":["Q40Q9N063P","2P3VWU3H10","6T6CO7R3Z5","W9FZA51AS1","56K0VVT47P","S003A158SB","01G9XEA93N","79N6542N18","C88X29Y479","E4GA8884NN","I76KB35JEV","ETJ7Z6XBU4","0YPR65R21J","O642E96711","91D9GV0Z28","900961Z8VR"],"route":["ORAL"],"spl_id":["28fb3178-9aac-406f-a82a-de53d0876f67"],"brand_name":["BHI Migraine"],"spl_set_id":["11cad8ba-6914-420e-bab0-4ca37d33f2e6"],"package_ndc":["62795-1019-3"],"product_ndc":["62795-1019"],"generic_name":["ACETIC ACID, ARANEUS DIADEMATUS, ASAFETIDA, BRYONIA ALBA WHOLE, TRIBASIC CALCIUM PHOSPHATE, ACTIVATED CHARCOAL, CINCHONA OFFICINALIS BARK, MARSDENIA CONDURANGO BARK, TUBOCURARINE CHLORIDE, KALMIA LATIFOLIA LEAF, LYCOPODIUM CLAVATUM SPORE, SODIUM SULFATE, PHOSPHORIC ACID, PULSATILLA VULGARIS, CLAVICEPS PURPUREA SCLEROTIUM, AND SILICON DIOXIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ACETIC ACID","ACTIVATED CHARCOAL","ARANEUS DIADEMATUS","ASAFETIDA","BRYONIA ALBA WHOLE","CINCHONA OFFICINALIS BARK","CLAVICEPS PURPUREA SCLEROTIUM","KALMIA LATIFOLIA LEAF","LYCOPODIUM CLAVATUM SPORE","MARSDENIA CONDURANGO BARK","PHOSPHORIC ACID","PULSATILLA VULGARIS","SILICON DIOXIDE","SODIUM SULFATE","STRYCHNINE NITRATE","TRIBASIC CALCIUM PHOSPHATE","TUBOCURARINE CHLORIDE"],"manufacturer_name":["MediNatura Inc"],"is_original_packager":[true]},"purpose":["PURPOSE Migraine Relief Tablets Relieves: • Headache Pain • Headache Pain with Nausea • Neck Muscle Tension"],"version":"5","warnings":["WARNINGS If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If symptoms persist or worsen, a health professional should be consulted. Ask a doctor before use if you have never had migraines diagnosed by a health professional, you have a headache that is different from your usual migraines, you have the worst headache of your life, you have fever and stiff neck, you have a migraine so severe as to require bed rest. Do not use if known sensitivity to BHI Migraine or any of its ingredients exists."],"effective_time":"20230928","active_ingredient":["INGREDIENT SECTIONS Each tablet contains: Aceticum acidum 6X, *Aranea diadema 8X, *Asafoetida 6X, *Bryonia alba 30X, Calcarea phosphorica 10X, *Carbo vegetabilis 10X, *Cinchona officinalis 4X, *Condurango 4X, *Curare 10X, *Kalmia latifolia 8X, *Lycopodium clavatum 6X, Natrum sulphuricum 6X, Phosphoricum acidum 6X, *Pulsatilla 4X, *Secale cornutum 6X, *Silicea 10X, Strychninum nitricum 8X 17.6 mg each. *Natural Ingredients"],"inactive_ingredient":["INACTIVE INGREDIENTS Inactive Ingredients: Dextrose, Magnesium Stearate, Maltodextrin"],"indications_and_usage":["USES For the temporary relief of minor migraine headache pain, headache pain with nausea, headache due to simple nervous tension"],"dosage_and_administration":["DIRECTIONS At first sign of symptoms: Adults: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Standard dosage: Adults: Take 1-2 tablets every 4 to 6 hours. Do not exceed 12 tablets in 24 hours. For children under 18, consult your health professional. Allow tablets to dissolve completely in the mouth, do not swallow."],"spl_product_data_elements":["BHI Migraine ACETIC ACID, ARANEUS DIADEMATUS, ASAFETIDA, BRYONIA ALBA WHOLE, TRIBASIC CALCIUM PHOSPHATE, ACTIVATED CHARCOAL, CINCHONA OFFICINALIS BARK, MARSDENIA CONDURANGO BARK, TUBOCURARINE CHLORIDE, KALMIA LATIFOLIA LEAF, LYCOPODIUM CLAVATUM SPORE, SODIUM SULFATE, PHOSPHORIC ACID, PULSATILLA VULGARIS, CLAVICEPS PURPUREA SCLEROTIUM, and SILICON DIOXIDE ACETIC ACID ACETIC ACID ARANEUS DIADEMATUS ARANEUS DIADEMATUS ASAFETIDA ASAFETIDA BRYONIA ALBA WHOLE BRYONIA ALBA WHOLE TRIBASIC CALCIUM PHOSPHATE CALCIUM CATION ACTIVATED CHARCOAL ACTIVATED CHARCOAL CINCHONA OFFICINALIS BARK CINCHONA OFFICINALIS BARK MARSDENIA CONDURANGO BARK MARSDENIA CONDURANGO BARK TUBOCURARINE CHLORIDE TUBOCURARINE KALMIA LATIFOLIA LEAF KALMIA LATIFOLIA LEAF LYCOPODIUM CLAVATUM SPORE LYCOPODIUM CLAVATUM SPORE SODIUM SULFATE SODIUM SULFATE ANHYDROUS PHOSPHORIC ACID PHOSPHORIC ACID PULSATILLA VULGARIS PULSATILLA VULGARIS CLAVICEPS PURPUREA SCLEROTIUM CLAVICEPS PURPUREA SCLEROTIUM SILICON DIOXIDE SILICON DIOXIDE STRYCHNINE NITRATE STRYCHNINE MAGNESIUM STEARATE MALTODEXTRIN DEXTROSE Leafman"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN Keep out of reach of children."],"package_label_principal_display_panel":["Add image transcription here... BHI Migraine Tablet.jpg"]},"tags":[{"label":"calcium phosphate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A12AA01","category":"atc"},{"label":"Topical","category":"route"},{"label":"Dental","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Liquid","category":"form"},{"label":"Paste","category":"form"},{"label":"Active","category":"status"},{"label":"Breastfeeding (mother)","category":"indication"},{"label":"Hypocalcemia","category":"indication"},{"label":"Osteoporosis","category":"indication"},{"label":"Postmenopausal osteoporosis","category":"indication"},{"label":"Pregnancy, function","category":"indication"},{"label":"Biocompatible Materials","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"169 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"136 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"132 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"131 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"131 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"108 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"105 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"97 reports"},{"date":"","signal":"PAIN IN EXTREMITY","source":"FDA FAERS","actionTaken":"94 reports"}],"commonSideEffects":[],"contraindications":["Arteriosclerosis obliterans","Autoimmune disease","Constipation","Dehydration","Depressive disorder","Diabetes mellitus","Disease of liver","Diverticular disease","Gastroenteritis","Hemochromatosis","Hemolytic anemia","Hemosiderosis","Hypercalcemia","Hypercalciuria","Hyperparathyroidism","Hyperphosphatemia","Hypervitaminosis D","Kidney disease","Kidney stone","Mental handicap","Neoplasm of prostate","Peptic ulcer","Poisoning by digitalis glycoside","Repeated Blood Transfusions","Sarcoidosis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=calcium phosphate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:01:35.739392+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Calcium Phosphate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:01:43.500546+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:01:41.323967+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=calcium phosphate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:01:41.771787+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:01:31.590804+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:01:31.590864+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:01:44.041668+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107567/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:01:43.147625+00:00"}},"allNames":"tricalcium phosphate","offLabel":[],"synonyms":["calcium phosphate","tribasic calcium phosphate","tricalcium phosphate"],"timeline":[],"brandName":"Tricalcium Phosphate","ecosystem":[{"indication":"Breastfeeding (mother)","otherDrugs":[{"name":"ascorbic acid","slug":"ascorbic-acid","company":""},{"name":"doconexent","slug":"doconexent","company":""},{"name":"docusate sodium","slug":"docusate-sodium","company":""},{"name":"eicosapentaenoic acid","slug":"eicosapentaenoic-acid","company":""}],"globalPrevalence":null},{"indication":"Hypocalcemia","otherDrugs":[{"name":"calcifediol","slug":"calcifediol","company":""},{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"}],"globalPrevalence":200000000},{"indication":"Postmenopausal osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"calcium citrate","slug":"calcium-citrate","company":""}],"globalPrevalence":200000000},{"indication":"Pregnancy, function","otherDrugs":[{"name":"doconexent","slug":"doconexent","company":""},{"name":"docusate sodium","slug":"docusate-sodium","company":""},{"name":"eicosapentaenoic acid","slug":"eicosapentaenoic-acid","company":""},{"name":"ferrous fumarate","slug":"ferrous-fumarate","company":"Gd Searle Llc"}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"calcium phosphate","explanation":"","oneSentence":"","technicalDetail":"Tricalcium phosphate is a calcium salt that is absorbed by the body and used to regulate calcium levels, which is essential for maintaining bone health and preventing conditions such as osteoporosis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Calcium_phosphate","title":"Calcium phosphate","extract":"The term calcium phosphate refers to a family of materials and minerals containing calcium ions (Ca2+) together with inorganic phosphate anions. Some so-called calcium phosphates contain oxide and hydroxide as well. Calcium phosphates are white solids of nutritional value and are found in many living organisms, e.g., bone mineral and tooth enamel. In milk, it exists in a colloidal form in micelles bound to casein protein with magnesium, zinc, and citrate–collectively referred to as colloidal calcium phosphate (CCP). Various calcium phosphate minerals, which often are not white owing to impurities, are used in the production of phosphoric acid and fertilizers. Overuse of certain forms of calcium phosphate can lead to nutrient-containing surface runoff and subsequent adverse effects upon receiving waters such as algal blooms and eutrophication (over-enrichment with nutrients and minerals)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4441","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=calcium%20phosphate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=calcium phosphate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Calcium_phosphate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:08:06.294607","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:46.934936+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"calcium gluconate","drugSlug":"calcium-gluconate","fdaApproval":"","patentExpiry":"Jul 25, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"calcium carbonate","drugSlug":"calcium-carbonate","fdaApproval":"2000-10-16","relationship":"same-class"},{"drugName":"calcium chloride","drugSlug":"calcium-chloride","fdaApproval":"1971-03-22","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcium glycerylphosphate","drugSlug":"calcium-glycerylphosphate","fdaApproval":"","relationship":"same-class"},{"drugName":"calcium glucoheptonate","drugSlug":"calcium-glucoheptonate","fdaApproval":"1972-12-04","relationship":"same-class"},{"drugName":"calcium citrate","drugSlug":"calcium-citrate","fdaApproval":"","relationship":"same-class"}],"genericName":"calcium phosphate","indications":{"approved":[{"name":"Breastfeeding (mother)","source":"DrugCentral","snomedId":413712001,"regulator":"FDA","eligibility":null},{"name":"Hypocalcemia","source":"DrugCentral","snomedId":5291005,"regulator":"FDA","eligibility":null},{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Pregnancy, function","source":"DrugCentral","snomedId":289908002,"regulator":"FDA"}],"offLabel":[{"name":"Prevention of Fetal Neural Tube Defects during Pregnancy","source":"DrugCentral","drugName":"calcium phosphate","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"calcium-gluconate","brandName":"calcium gluconate","genericName":"calcium gluconate","approvalYear":"","relationship":"same-class"},{"drugId":"calcium-carbonate","brandName":"calcium carbonate","genericName":"calcium carbonate","approvalYear":"2000","relationship":"same-class"},{"drugId":"calcium-chloride","brandName":"calcium chloride","genericName":"calcium chloride","approvalYear":"1971","relationship":"same-class"},{"drugId":"calcium-glycerylphosphate","brandName":"calcium glycerylphosphate","genericName":"calcium glycerylphosphate","approvalYear":"","relationship":"same-class"},{"drugId":"calcium-glucoheptonate","brandName":"calcium glucoheptonate","genericName":"calcium glucoheptonate","approvalYear":"1972","relationship":"same-class"},{"drugId":"calcium-citrate","brandName":"calcium citrate","genericName":"calcium citrate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT07244991","phase":"NA","title":"Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2026-01-04","conditions":["Dental Caries","Streptococcus Mutans","Tooth Demineralization","Orthodontic Appliances, Fixed"],"enrollment":200,"completionDate":"2027-11"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT06673888","phase":"NA","title":"Assessment of Alkasite Restorative Material Versus Resin Modified Glass Ionomer in Class V Cavities: A Clinical Trial","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-12-01","conditions":["Class V Dental Caries"],"enrollment":50,"completionDate":"2025-12-01"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT07465367","phase":"NA","title":"Methionine for CaPhos Stone","status":"NOT_YET_RECRUITING","sponsor":"Ryan L Steinberg","startDate":"2026-04-01","conditions":["Calcium Phosphate Kidney Stones"],"enrollment":15,"completionDate":"2027-04"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":3,"completionDate":"2026-08-31"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT07449169","phase":"NA","title":"Diode Laser Plus CPP-ACPF vs CPP-ACPF Alone for Dentin Hypersensitivity","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-04-01","conditions":["Dentin Hypersensitivity","Tooth Hypersensitivity"],"enrollment":70,"completionDate":"2027-10-01"},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":288,"completionDate":"2029-12-31"},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":1450,"completionDate":"2027-12-31"},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":["Newly Diagnosed Primary Amyloidosis","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":21,"completionDate":"2027-05-18"},{"nctId":"NCT04764942","phase":"PHASE1,PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":39,"completionDate":"2027-12-17"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":21,"completionDate":"2028-02-01"},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":["Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"],"enrollment":158,"completionDate":"2029-06-30"},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":["AL Amyloidosis"],"enrollment":11,"completionDate":"2026-07-24"},{"nctId":"NCT07415421","phase":"NA","title":"Parathyroidectomy After Kidney Transplantation","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-01-20","conditions":["Hyperparathyroidism","Kidney Transplantation Recipients"],"enrollment":85,"completionDate":"2030-12-31"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT04966507","phase":"PHASE2","title":"Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-02-17","conditions":["Gonorrhea"],"enrollment":89,"completionDate":"2025-12-12"},{"nctId":"NCT07408076","phase":"PHASE1,PHASE2","title":"Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02-01","conditions":["Kidney Stones, Urolithiasis, Hypocitraturia","Nephrolithiasis"],"enrollment":30,"completionDate":"2028-02-01"},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":["Mantle Cell Lymphoma"],"enrollment":51,"completionDate":"2027-03-22"},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":["Low Grade Glioma","Malignant Brain Glioma","Malignant Brain Neoplasm","Meningioma"],"enrollment":200,"completionDate":"2028-07-30"},{"nctId":"NCT07399340","phase":"NA","title":"A Comparative Evaluation of the Role of Self-Adhesive Flowable Composite in Enhancing Sealant Retention Versus Conventional Pits and Fissure Sealant With and Without Fissurotomy in Permanent Molars","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03","conditions":["Pits and Fissure Sealants"],"enrollment":88,"completionDate":"2027-06"},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":["Multiple Myeloma"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":["Plasmacytoma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":35,"completionDate":"2024-07-24"},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":["B-Cell Non-Hodgkin Lymphoma (B-NHL)"],"enrollment":216,"completionDate":"2027-05-14"},{"nctId":"NCT06973226","phase":"","title":"Evaluation of the Safety and Performance of the Neocement®","status":"RECRUITING","sponsor":"Bioceramed","startDate":"2025-09-05","conditions":["Bone Defects","Orthopaedic Surgery (30 Minutes or Longer)"],"enrollment":80,"completionDate":"2027-06"},{"nctId":"NCT06973239","phase":"","title":"Evaluation of the Safety and Performance of the Neocement® Inject P","status":"RECRUITING","sponsor":"Bioceramed","startDate":"2025-09-05","conditions":["Bone Defects","Orthopaedic Surgery (30 Minutes or Longer)"],"enrollment":80,"completionDate":"2027-06"},{"nctId":"NCT07179510","phase":"","title":"Evaluation of the Safety and Performance of the Neocement® Inject P: A Prospective Observational Study in Dental Area","status":"RECRUITING","sponsor":"Bioceramed","startDate":"2025-10-06","conditions":["Bone Augmentation"],"enrollment":66,"completionDate":"2027-10"},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":["ISS Stage III Plasma Cell Myeloma","Multiple Myeloma"],"enrollment":17,"completionDate":"2028-11-20"},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":27,"completionDate":"2026-12-31"},{"nctId":"NCT02943746","phase":"NA","title":"Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-11","conditions":["Premature Infants"],"enrollment":118,"completionDate":"2021-04-30"},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":["Recurrent Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hairy Cell Leukemia","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis"],"enrollment":13,"completionDate":"2025-08-05"},{"nctId":"NCT07368946","phase":"NA","title":"Phosphate Assessment in Chronic Kidney Disease Patients Study","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-09","conditions":["Chronic Kidney Disease (Stage 3-4)","Chronic Kidney Disease Mineral and Bone Disorder"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT07177521","phase":"NA","title":"Primary Stability and Peri-implant Outcomes of Short Implants in Post-extraction Single-tooth Sites","status":"RECRUITING","sponsor":"University of Bari Aldo Moro","startDate":"2025-01-10","conditions":["Edentulous Jaw","Tooth Loss","Toothless Mouth"],"enrollment":10,"completionDate":"2026-08-10"},{"nctId":"NCT07371117","phase":"PHASE2","title":"Effect Of Silverdiamine Fluoride Gel, Sodium Fluoride With CPP-ACP, APF On Early Childhood Caries - A Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jazan","startDate":"2025-11-01","conditions":["Early Childhood Caries (ECC)","Dental Caries"],"enrollment":90,"completionDate":"2026-02"},{"nctId":"NCT07299838","phase":"","title":"Palopegteriparatide in Chronic Hypoparathyroidism","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-06-01","conditions":["Hypoparathyroidism"],"enrollment":90,"completionDate":"2025-10-23"},{"nctId":"NCT06616584","phase":"PHASE2,PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":378,"completionDate":"2028-12-31"},{"nctId":"NCT07055282","phase":"EARLY_PHASE1","title":"SGLT2i in Kidney Stones","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-11-20","conditions":["Kidney Stones"],"enrollment":32,"completionDate":"2027-12-31"},{"nctId":"NCT06627751","phase":"PHASE2","title":"Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-05-01","conditions":["Extramedullary Disease in Multiple Myeloma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":28,"completionDate":"2030-05-01"},{"nctId":"NCT07330193","phase":"NA","title":"Flowable Resin Composite: Two-Year Clinical Performance in Class I Restorations","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-06-22","conditions":["Class I Dental Caries"],"enrollment":10,"completionDate":"2025-03-20"},{"nctId":"NCT03808610","phase":"PHASE1,PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":["Lymphoma"],"enrollment":40,"completionDate":"2034-01-31"},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":["Pentoxifylline","Inflammatory Markers","Non-Diabetic","Chronic Kidney Disease"],"enrollment":42,"completionDate":"2023-08-31"},{"nctId":"NCT05472883","phase":"NA","title":"Identification of Human Biomarkers Predictive of Diabetes Remission in Type 2 Diabetes Patient (BARIAKINES)","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2023-02-27","conditions":["Type 2 Diabetes"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT07193056","phase":"","title":"The CPH-MBD Cohort","status":"NOT_YET_RECRUITING","sponsor":"Herlev Hospital","startDate":"2025-12","conditions":["Chronic Kidney Disease Mineral and Bone Disorder","Chronic Kidney Disease (CKD)","Bone Markers"],"enrollment":1000,"completionDate":"2055-01"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT07312981","phase":"","title":"The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-12-15","conditions":["CKD","Renal Insufficiency Chronic","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder","Pre-dialysis"],"enrollment":50,"completionDate":"2029-05-15"},{"nctId":"NCT07296302","phase":"NA","title":"Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Agnaldo Rocha de Souza Junior","startDate":"2026-02","conditions":["Alveolar Ridge Augmentation","Bone Grafting","Antibiotic Prophylaxis"],"enrollment":150,"completionDate":"2027-08"},{"nctId":"NCT03583255","phase":"PHASE2","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-29","conditions":["Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm"],"enrollment":99,"completionDate":"2027-12-31"},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2028-12-01"},{"nctId":"NCT04540835","phase":"NA","title":"Evaluation of the Effectiveness of Calcium Phosphate Containing Desensitizer on Postoperative Sensitivity","status":"COMPLETED","sponsor":"Baskent University","startDate":"2021-10-01","conditions":["Postoperative Pain"],"enrollment":50,"completionDate":"2022-12-01"},{"nctId":"NCT06383572","phase":"PHASE1,PHASE2","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-26","conditions":["Lymphodepleting Chemotherapy","Myeloid Malignancies"],"enrollment":44,"completionDate":"2029-04-01"},{"nctId":"NCT02918344","phase":"","title":"Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Osteotomies","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2017-03-01","conditions":["Jaw Anomalies","Infection"],"enrollment":196,"completionDate":"2020-04-30"},{"nctId":"NCT07289932","phase":"NA","title":"\"Clinical Evaluation of Self-Assembling Peptides Versus Tri-Calcium Phosphate Based Varnish in Treatment of White Spot Lesions; Split-Mouth Randomized Clinical Trial\"","status":"ENROLLING_BY_INVITATION","sponsor":"Ain Shams University","startDate":"2024-02-20","conditions":["White Spot Lesions"],"enrollment":38,"completionDate":"2026-12"},{"nctId":"NCT07285421","phase":"NA","title":"Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-01","conditions":["Enamel Renal Syndrome"],"enrollment":30,"completionDate":"2029-10-30"},{"nctId":"NCT04551131","phase":"PHASE1,PHASE2","title":"Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-07-13","conditions":["Hemophagocytic Lymphohistiocytosis"],"enrollment":10,"completionDate":"2026-08"},{"nctId":"NCT02553460","phase":"PHASE1,PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2031-10"},{"nctId":"NCT03024008","phase":"PHASE1,PHASE2","title":"Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II","status":"RECRUITING","sponsor":"BonusBio Group Ltd","startDate":"2017-07-27","conditions":["Bone Fracture"],"enrollment":40,"completionDate":"2027-06"},{"nctId":"NCT07268742","phase":"","title":"Free Vitamin D and Steroid Metabolism in Endocrine Disorders","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-06-01","conditions":["Vitamin D","Vitamin D and Calcium Homeostasis"],"enrollment":930,"completionDate":"2029-10"},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Adult Acute Lymphoblastic Leukemia in Complete Remission","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Untreated Adult Acute Lymphoblastic Leukemia"],"enrollment":88,"completionDate":"2027-10-31"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT05329129","phase":"","title":"OssDsign® Spine Registry Study (\"Propel\")","status":"RECRUITING","sponsor":"OssDsign","startDate":"2022-03-23","conditions":["Degenerative Disc Disease","Spinal Stenosis"],"enrollment":450,"completionDate":"2027-04-01"},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":488,"completionDate":"2026-03-25"},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":452,"completionDate":"2026-10-23"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":["Blastoid Variant Mantle Cell Lymphoma","Mantle Cell Lymphoma","Pleomorphic Variant Mantle Cell Lymphoma"],"enrollment":131,"completionDate":"2027-06-30"},{"nctId":"NCT07240246","phase":"NA","title":"Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults","status":"RECRUITING","sponsor":"FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","startDate":"2025-10-24","conditions":["GLP-1","Obesity &Amp; Overweight","Dietary Supplement"],"enrollment":40,"completionDate":"2026-03-11"},{"nctId":"NCT07229105","phase":"NA","title":"Comparative Effectiveness of Remineralization Agents on Attachment-Associated Demineralization in Clear Aligner Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2024-08-12","conditions":["White Spot Lesions","Demineralization","Dental Caries","Orthodontic Treatment"],"enrollment":40,"completionDate":"2025-03-28"},{"nctId":"NCT05514990","phase":"PHASE1,PHASE2","title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-10-07","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":10,"completionDate":"2027-08-22"},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":["Acute Lymphoblastic Leukemia","Philadelphia Chromosome-Negative Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia (ALL)","Leukemia"],"enrollment":67,"completionDate":"2035-07-31"},{"nctId":"NCT03367156","phase":"PHASE2","title":"Dexamethasone in Controlling Dyspnea in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-04","conditions":["Dyspnea","Malignant Neoplasm"],"enrollment":135,"completionDate":"2025-12-31"},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2026-11-01"},{"nctId":"NCT03132454","phase":"PHASE1","title":"Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-25","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":32,"completionDate":"2027-12-31"},{"nctId":"NCT05392946","phase":"PHASE1,PHASE2","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-08-11","conditions":["Plasma Cell Myeloma"],"enrollment":49,"completionDate":"2028-05-31"},{"nctId":"NCT03110224","phase":"","title":"SCP® Observational Study of the Knee","status":"TERMINATED","sponsor":"Zimmer Biomet","startDate":"2012-09-18","conditions":["Bone Marrow Edema"],"enrollment":516,"completionDate":"2023-05-31"},{"nctId":"NCT03763162","phase":"PHASE2","title":"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-17","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":40,"completionDate":"2027-10-30"},{"nctId":"NCT07212985","phase":"NA","title":"Horizontal Anterior Maxillary Ridge Augmentation Using Autogenous Ring Block Grafts Combined With Particulate Xenogeneic Bone Versus Biphasic Beta-tri-calcium Phosphate Sulphate EthOss Graft: A Clinical Study","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-01-05","conditions":["Implant Dentistry"],"enrollment":40,"completionDate":"2024-06-18"},{"nctId":"NCT06785415","phase":"PHASE1,PHASE2","title":"Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-18","conditions":["Recurrent Multiple Myeloma"],"enrollment":37,"completionDate":"2031-04-01"},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Nodal Marginal Zone Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":25,"completionDate":"2030-08-01"},{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":["Breast Carcinoma"],"enrollment":1363,"completionDate":"2024-04-13"},{"nctId":"NCT04776395","phase":"PHASE2","title":"Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-11-02","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":68,"completionDate":"2029-09-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Liquid, Paste","formulations":[{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Prenaissance"},{"form":"LIQUID","route":"ORAL","productName":"Dairy Allergen Mix"},{"form":"LIQUID","route":"ORAL","productName":"CS Bone"},{"form":"PASTE","route":"DENTAL","productName":"KUNDAL Sensitive Dental Care Tooth (Apple Chamomile Mint)"},{"form":"PASTE","route":"TOPICAL","productName":"Exoden Sensitive"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"DIO Enamel Coating Pen Pro Tooth"}]},"crossReferences":{"NUI":"N0000148058","MMSL":"17895","NDDF":"005047","UNII":"91D9GV0Z28","VUID":"4019973","CHEBI":"CHEBI:9679","VANDF":"4019973","RXNORM":"1919","UMLSCUI":"C0006711","chemblId":"CHEMBL2107567","ChEMBL_ID":"CHEMBL2107567","DRUGBANK_ID":"DB11348","PUBCHEM_CID":"24456","SNOMEDCT_US":"419939009","SECONDARY_CAS_RN":"1306-06-5","MESH_SUPPLEMENTAL_RECORD_UI":"C020243"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":21576,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"A12AA01","allCodes":["A12AA01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41905050","title":"\"Bentogypsum\", a phosphoric acid purification residue: Characterization and implications for environmental and human health risk in Gabes (SE Tunisia).","journal":"Journal of hazardous materials"},{"date":"2026 Mar 20","pmid":"41899898","title":"Clinical Evidence on Resorbable Calcium Phosphate Biomaterials for Alveolar Bone Regeneration: A Scoping Review Focusing on Brushite, Monetite, and Tricalcium Phosphates.","journal":"Bioengineering (Basel, Switzerland)"},{"date":"2026 Mar 10","pmid":"41898411","title":"Time-Course Evaluation of the In Vivo Resorption Process of Calcium Phosphates/Poly(lactide-co-glycolide) Composites Using Radiological Imaging and Histology.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 6","pmid":"41897332","title":"Synthetic Modulators of the Vitamin D Receptor: From Structural Innovation to Disease-Specific Applications.","journal":"Biomolecules"},{"date":"2026 Mar 26","pmid":"41895242","title":"Longitudinal evaluation of salivary biomarkers and white spot lesion development in patients undergoing fixed orthodontic treatment: A prospective cohort study.","journal":"International orthodontics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:46.934936+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}